drugset
drugset / Trial / NCT01169857

Velcade for Proliferative Lupus Nephritis

NCT01169857 ↗

Phase 4 Withdrawn The Rogosin Institute Weill Medical College of Cornell University · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.

Timeline

Start
2010-08
Primary completion
2012-08
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 —

Indications

lupus nephritis proteinuria